

Jan Delabie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11071/publications.pdf>

Version: 2024-02-01

239
papers

34,444
citations

9786

73
h-index

3579

181
g-index

242
all docs

242
docs citations

242
times ranked

22286
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	1.4	3,574
2	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	27.0	3,474
3	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	27.0	1,443
4	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	27.8	1,402
5	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	27.0	1,293
6	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	27.8	1,292
7	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	27.0	1,141
8	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.5	1,002
9	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	7.1	868
10	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	16.8	848
11	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	27.0	824
12	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	1.6	824
13	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	12.6	784
14	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	27.8	759
15	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	7.0	577
16	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo "purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i> , 2008, 112, 2687-2693.	1.4	571
17	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	1.4	518
18	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. <i>Journal of Clinical Oncology</i> , 2012, 30, 3093-3099.	1.6	490

#	ARTICLE	IF	CITATIONS
19	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	1.4	435
20	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	1.6	426
21	Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2010, 115, 1026-1036.	1.4	353
22	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	1.4	348
23	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	3.5	345
24	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005, 106, 4315-4321.	1.4	330
25	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	1.4	308
26	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	1.4	296
27	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 961-968.	1.6	277
28	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	27.8	276
29	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	16.8	263
30	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	3.8	262
31	Loss of signalling via $\text{G}\alpha 13$ in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014, 516, 254-258.	27.8	253
32	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1686-1694.	3.7	251
33	Nordic <i>MCL</i> 2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <i>BEAM</i> or <i>BEAC</i> + autologous stem-cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	2.5	241
34	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	1.4	226
35	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	1.4	177
36	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	1.4	173

#	ARTICLE	IF	CITATIONS
37	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<sc>MCL</sc>2): prolonged remissions without survival plateau. British Journal of Haematology, 2016, 175, 410-418.	2.5	170
38	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 2010, 115, 1530-1533.	1.4	167
39	The Value of Anti-Pax-5 Immunostaining in Routinely Fixed and Paraffin-Embedded Sections. American Journal of Surgical Pathology, 2002, 26, 1343-1350.	3.7	166
40	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. Journal of Clinical Oncology, 2007, 25, 1216-1222.	1.6	166
41	Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood, 2003, 102, 3753-3758.	1.4	159
42	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood, 2013, 122, 3599-3606.	1.4	156
43	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. Clinical Cancer Research, 2011, 17, 7785-7795.	7.0	152
44	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood, 2013, 121, 1367-1376.	1.4	147
45	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica, 2012, 97, 270-278.	3.5	146
46	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454.	7.1	143
47	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. British Journal of Haematology, 2007, 136, 286-293.	2.5	142
48	Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica, 2014, 99, 497-504.	3.5	142
49	Marginal-Zone B Cells in the Human Lymph Node and Spleen Show Somatic Hypermutations and Display Clonal Expansion. Blood, 1999, 93, 226-234.	1.4	138
50	Mutation and genomic deletion status of <i>ataxia telangiectasia mutated</i> (<i>ATM</i>) and <i>p53</i> confer specific gene expression profiles in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357.	7.1	138
51	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. Cancer Discovery, 2014, 4, 480-493.	9.4	130
52	The Transcription Factor PU.1, Necessary for B-Cell Development Is Expressed in Lymphocyte Predominance, But Not Classical Hodgkin's Disease. American Journal of Pathology, 2001, 159, 1807-1814.	3.8	123
53	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood, 2010, 116, 953-961.	1.4	122
54	Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. British Journal of Haematology, 2012, 156, 225-233.	2.5	116

#	ARTICLE	IF	CITATIONS
55	Translocation (11;14): A cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. <i>Journal of Pathology</i> , 1991, 163, 13-18.	4.5	113
56	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	1.6	113
57	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	2.5	110
58	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	1.4	110
59	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	1.4	110
60	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	1.4	103
61	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	1.6	102
62	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	3.5	100
63	Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. <i>BMC Bioinformatics</i> , 2002, 3, 36.	2.6	99
64	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	1.4	97
65	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. <i>Cancer Research</i> , 2005, 65, 2199-2206.	0.9	93
66	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	16.8	93
67	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	1.4	90
68	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. <i>Haematologica</i> , 2010, 95, 509-513.	3.5	89
69	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	1.4	89
70	Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. <i>Blood</i> , 2005, 105, 2869-2876.	1.4	88
71	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	3.5	87
72	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008, 93, 1327-1334.	3.5	80

#	ARTICLE	IF	CITATIONS
73	MicroRNA profiles of t(14;18)â€“negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	1.4	77
74	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1âˆ“ mantle cell lymphoma. <i>Blood</i> , 2019, 133, 940-951.	1.4	77
75	Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. <i>Blood</i> , 2001, 97, 1845-1853.	1.4	75
76	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	1.4	72
77	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.7	71
78	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017, 129, 759-770.	1.4	69
79	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	1.4	68
80	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. <i>Clinical Cancer Research</i> , 2011, 17, 3727-3732.	7.0	68
81	T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. <i>Haematologica</i> , 2010, 95, 440-448.	3.5	66
82	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	1.4	64
83	Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases. <i>Journal of Hepatology</i> , 1997, 27, 922-927.	3.7	63
84	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	3.7	63
85	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017, 130, 1819-1831.	1.4	62
86	Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. <i>BMC Immunology</i> , 2004, 5, 20.	2.2	59
87	Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. <i>Blood</i> , 2010, 116, 1489-1497.	1.4	58
88	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	7.1	57
89	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 102-114.	2.5	56
90	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq0 0 0 rgBT/Overlock 10 Tf 428-435.	2.0	56

#	ARTICLE	IF	CITATIONS
91	Lymphomatous Polyposis. American Journal of Surgical Pathology, 1996, 20, 442-452.	3.7	54
92	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296.	1.4	53
93	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2005, 46, 693-701.	1.3	51
94	Some desmoid tumors are characterized by trisomy 8. Genes Chromosomes and Cancer, 1994, 10, 131-135.	2.8	49
95	Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization. Oncogene, 2005, 24, 1159-1173.	5.9	49
96	NOTCH2 mutations in marginal zone lymphoma. Haematologica, 2008, 93, 1107-1109.	3.5	49
97	Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood, 2014, 123, 1051-1054.	1.4	49
98	Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood, 2011, 118, 3331-3339.	1.4	47
99	Clinical and Histopathological Features of Folliculotropic Mycosis Fungoides: A Norwegian Patient Series. Acta Dermato-Venereologica, 2013, 93, 325-329.	1.3	46
100	Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma. Journal of Molecular Diagnostics, 2004, 6, 297-307.	2.8	45
101	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood, 2015, 125, 82-89.	1.4	45
102	How Reliable is Histologic Examination of Bone Marrow Trepine Biopsy Specimens for the Staging of Non-Hodgkin Lymphoma?: A Study of Hairy Cell Leukemia and Mantle Cell Lymphoma Involvement of the Bone Marrow Trepine Specimen by Histologic, Immunohistochemical, and Polymerase Chain Reaction Techniques. American Journal of Clinical Pathology, 1999, 111, 179-184.	0.7	44
103	High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology, 2011, 152, 600-610.	2.5	44
104	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood, 2015, 125, 2669-2677.	1.4	44
105	Splenic Marginal Zone Lymphoma with Villous Lymphocytes Shows On-Going Immunoglobulin Gene Mutations. American Journal of Pathology, 2003, 162, 681-689.	3.8	39
106	Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 78-87.	2.8	37
107	Distribution of mRNA coding for Alpha-2-macroglobulin, the murinoglobulins, the Alpha-2-macroglobulin receptor and the Alpha-2-macroglobulin receptor associated protein during mouse embryogenesis and in adult tissues. Differentiation, 1994, 55, 213-223.	1.9	36
108	Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. British Journal of Haematology, 1998, 102, 1301-1306.	2.5	36

#	ARTICLE	IF	CITATIONS
109	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	2.8	36
110	Characterization of a novel immunoglobulin-like domain containing receptor. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 970-978.	2.1	35
111	The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. <i>Journal of Pathology</i> , 2006, 208, 431-438.	4.5	35
112	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	2.0	34
113	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2015, 143, 797-806.	0.7	31
114	Concurrent Lymphocyte Predominance Hodgkin's Disease and T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 355-362.	3.7	30
115	Distribution of non-lymphoid, inflammatory cells in chronic HBV infection. <i>Journal of Pathology</i> , 1990, 160, 223-230.	4.5	29
116	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.7	29
117	Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. <i>Epigenetics</i> , 2014, 9, 428-436.	2.7	29
118	G-banding and molecular cytogenetic analyses of marginal zone lymphoma. <i>British Journal of Haematology</i> , 2005, 130, 890-901.	2.5	28
119	New probabilistic graphical models for genetic regulatory networks studies. <i>Journal of Biomedical Informatics</i> , 2005, 38, 443-455.	4.3	27
120	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, 654.	6.2	26
121	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma. <i>ISRN Oncology</i> , 2013, 2013, 1-4.	2.1	25
122	Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. <i>Blood Advances</i> , 2020, 4, 993-996.	5.2	25
123	T-cell lymphoma developing in Hodgkin's disease: Evidence for two clones. <i>Journal of Pathology</i> , 1993, 170, 239-248.	4.5	24
124	Transformation of B cell lymphoma to histiocytic sarcoma: somatic mutations of PAX-5 gene with loss of expression cannot explain transdifferentiation. <i>Journal of Hematopathology</i> , 2009, 2, 135-141.	0.4	24
125	Two courses of four weekly infusions of rituximab with or without interferon- γ : final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	1.3	24
126	Granulomatous Slack Skin With a Translocation t(3;9)(q12;p24). <i>American Journal of Surgical Pathology</i> , 2007, 31, 803-806.	3.7	23

#	ARTICLE	IF	CITATIONS
127	Comprehensive genome-wide transcription factor analysis reveals that a combination of high affinity and low affinity DNA binding is needed for human gene regulation. <i>BMC Genomics</i> , 2015, 16, S12.	2.8	23
128	Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e195-e198.	3.5	23
129	The Antigen-Presenting Cell Function of Reed-Sternberg Cells. <i>Leukemia and Lymphoma</i> , 1995, 18, 35-40.	1.3	22
130	Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 407-411.	2.8	22
131	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	2.5	22
132	Bone Marrow Histology in Monoclonal B-Cell Lymphocytosis Shows Various B-Cell Infiltration Patterns. <i>American Journal of Clinical Pathology</i> , 2013, 139, 390-395.	0.7	21
133	Concurrent mediastinal germ-cell tumour and haematological malignancy: Case report and short review of literature. <i>Acta Oncologica</i> , 2008, 47, 466-469.	1.8	20
134	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e91031.	2.5	19
135	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. <i>Haematologica</i> , 2009, 94, 596-598.	3.5	18
136	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. <i>BMC Cancer</i> , 2012, 12, 478.	2.6	18
137	Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. <i>Scientific Reports</i> , 2017, 7, 7040.	3.3	18
138	CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. <i>Blood Advances</i> , 2018, 2, 3506-3514.	5.2	18
139	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1742-1749.	1.3	17
140	Identification of Highly Methylated Genes across Various Types of B-Cell Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e79602.	2.5	16
141	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	5.1	15
142	Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. <i>British Journal of Haematology</i> , 1999, 106, 1045-1048.	2.5	14
143	Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. <i>Haematologica</i> , 2010, 95, 1334-1341.	3.5	13
144	A Gene Panel, Including LRP12, Is Frequently Hypermethylated in Major Types of B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e104249.	2.5	13

#	ARTICLE	IF	CITATIONS
145	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	1.3	13
146	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015, 67, 62-69.	2.9	12
147	Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review. <i>Pathology Research and Practice</i> , 2021, 226, 153589.	2.3	12
148	PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. <i>Journal of Pathology</i> , 2005, 206, 312-319.	4.5	11
149	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. <i>Blood</i> , 2007, 110, 348-348.	1.4	11
150	Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol. <i>Blood</i> , 2006, 108, 2438-2438.	1.4	11
151	Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. <i>European Journal of Haematology</i> , 2013, 91, 332-338.	2.2	10
152	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014, 124, 3016-3016.	1.4	10
153	Molecular Cloning of a Gene on Chromosome 19q12 Coding for a Novel Intracellular Protein: Analysis of Expression in Human and Mouse Tissues and in Human Tumor Cells, Particularly Reed-Sternberg Cells in Hodgkin Disease. <i>Genomics</i> , 1998, 54, 511-520.	2.9	9
154	t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations. <i>British Journal of Haematology</i> , 2005, 130, 845-851.	2.5	9
155	Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 559-565.	2.8	9
156	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009, 50, 1875-1878.	1.3	9
157	Restin in Hodgkin's Disease and Anaplastic Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1993, 12, 21-26.	1.3	7
158	Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features) Tj ETQq0 0 0 rgBT /Overlock 10	4.1	7
159	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations. <i>Blood</i> , 2007, 110, 360-360.	1.4	7
160	Characterization of the MicroRNA Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing. <i>Blood</i> , 2014, 124, 1626-1626.	1.4	7
161	Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 1119-1126.	4.2	6
162	Molecular cytogenetic analysis of leukemic mantle cell lymphoma with a cryptic t(11;14). <i>Cancer Genetics and Cytogenetics</i> , 2006, 165, 172-175.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Altered <scp>BCR</scp> and <scp>CD</scp>40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. British Journal of Haematology, 2012, 159, 0-0.	2.5	5
164	Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis. American Journal of Clinical Pathology, 2015, 144, 341-346.	0.7	5
165	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia and Lymphoma, 2017, 58, 623-632.	1.3	5
166	BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts. Frontiers in Genetics, 2019, 10, 282.	2.3	5
167	Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature. American Journal of Dermatopathology, 2017, 39, 134-139.	0.6	5
168	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T01). Blood, 2010, 116, 3566-3566.	1.4	5
169	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.. Blood, 2007, 110, LB1-LB1.	1.4	5
170	Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab. Blood, 2011, 118, 1641-1641.	1.4	5
171	Cytogenetic characterization of three cases of unusual B-cell non-Hodgkin's lymphoma. Cancer Genetics and Cytogenetics, 1991, 53, 229-235.	1.0	4
172	Hodgkin's Disease:Lineage and Clonality. American Journal of Clinical Pathology, 1995, 104, 368-370.	0.7	4
173	Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2007-2009.	1.3	4
174	The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia. BMJ Case Reports, 2015, 2015, bcr2015212103.	0.5	4
175	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T01). Blood, 2010, 116, 3565-3565.	1.4	4
176	Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma.. Blood, 2008, 112, 3339-3339.	1.4	4
177	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood, 2019, 134, 19-19.	1.4	4
178	Mantle cell lymphoma with features of marginal-zone lymphoma. Journal of Hematopathology, 2011, 4, 7-11.	0.4	3
179	Multiple Distinct T-Cell Clones in Folliculotropic Mycosis Fungoides. American Journal of Dermatopathology, 2014, 36, 972-976.	0.6	3
180	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. Haematologica, 2015, 100, e415-e418.	3.5	3

#	ARTICLE	IF	CITATIONS
181	High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01). <i>Blood</i> , 2011, 118, 331-331.	1.4	3
182	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. <i>Blood</i> , 2012, 120, 747-747.	1.4	3
183	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. <i>Blood</i> , 2014, 124, 3094-3094.	1.4	3
184	Binding of rabbit immunoglobulins to melanoma cells: a pitfall in the immunohistochemical study of malignant melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 421-422.	2.8	2
185	Localized lymphoid hyperplasia of the spleen: a rare benign condition grossly mimicking malignancy. <i>Journal of Hematopathology</i> , 2016, 9, 85-89.	0.4	2
186	Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 Motif: Suggestive of Lipid-antigen Selection?. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1081-1086.	1.3	2
187	DNA Methylation-Based Classification of Small B-Cell Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1774-1786.	2.8	2
188	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007, 110, 692-692.	1.4	2
189	R-CHOEP-14 Å— 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2â€³3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18â€³65 Years.. <i>Blood</i> , 2010, 116, 2805-2805.	1.4	2
190	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 679-679.	1.4	2
191	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013, 122, 1768-1768.	1.4	2
192	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. <i>Blood</i> , 2007, 110, 2631-2631.	1.4	2
193	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	1.4	2
194	Nuclear segmentation anomalies of neutrophils in neutrophilic dermatosis associated with myelodysplasia syndrome. <i>Journal of the American Academy of Dermatology</i> , 1991, 24, 1037.	1.2	1
195	Malignant Lymphoma of the Tongue with Unusual Cytology in a Pleural Effusion. <i>Acta Cytologica</i> , 2010, 54, 645-648.	1.3	1
196	Prognostic markers in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1588-1589.	1.3	1
197	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+â€³autologous stem-cell support: still very long survival but. <i>British Journal of Haematology</i> , 2012, 158, 815-816.	2.5	1
198	Primary Mediastinal Large B-Cell Lymphoma. , 2014, , 195-206.		1

#	ARTICLE	IF	CITATIONS
199	Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cell Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.. Blood, 2006, 108, 2042-2042.	1.4	1
200	Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1557-1557.	1.4	1
201	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415.	1.4	1
202	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 475-475.	1.4	1
203	Principles of the Pathology and Biology of Malignant Lymphomas. , 2014, , 3-16.		1
204	Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18. Blood, 2019, 134, 1488-1488.	1.4	1
205	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. Blood, 2021, 138, 1326-1326.	1.4	1
206	Concurrent Primary Follicular Lymphoma and a Mature Cystic Teratoma of the Ovary: A Case Report and Review of Literature. Case Reports in Pathology, 2022, 2022, 1-5.	0.3	1
207	Integrating whole genome sequencing, methylation, gene expression, topologically associated domain information in regulatory mutation prediction: A study of follicular lymphoma. Computational and Structural Biotechnology Journal, 2022, 20, 1726-1742.	4.1	1
208	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
209	Diffuse large B-cell lymphoma cycling off the main track. Leukemia and Lymphoma, 2011, 52, 358-359.	1.3	0
210	Keeping good and bad company: stromal cells in lymphoma. Leukemia and Lymphoma, 2012, 53, 1654-1655.	1.3	0
211	Malignant Phylloides Tumor and Acute Megakaryoblastic Leukemia Sharing a Common Clonal Origin. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	0
212	Personalized lymphoma diagnosis and treatment: recent advances. Diagnostic Histopathology, 2014, 20, 431-439.	0.4	0
213	Non-MALT Marginal Zone Lymphoma. , 2014, , 241-251.		0
214	VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.. Blood, 2006, 108, 2421-2421.	1.4	0
215	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. Blood, 2006, 108, 811-811.	1.4	0
216	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. Blood, 2008, 112, 1786-1786.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. Blood, 2008, 112, 2049-2049.	1.4	0
218	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. Blood, 2008, 112, 3604-3604.	1.4	0
219	NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of β T-Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent.. Blood, 2009, 114, 313-313.	1.4	0
220	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. Blood, 2009, 114, 620-620.	1.4	0
221	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922.	1.4	0
222	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	1.4	0
223	Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood, 2010, 116, 3107-3107.	1.4	0
224	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435.	1.4	0
225	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, 8074-8074.	1.6	0
226	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. Blood, 2012, 120, 2648-2648.	1.4	0
227	Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 75-75.	1.4	0
228	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue - An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	1.4	0
229	Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort. Blood, 2013, 122, 4272-4272.	1.4	0
230	Primary Cold Agglutinin Associated Lymphoproliferative Disease: A B-Cell Lymphoma Of The Bone Marrow Distinct From Lymphoplasmacytic Lymphoma. Blood, 2013, 122, 4335-4335.	1.4	0
231	Cutaneous T-Cell Lymphoma. , 2014, , 133-167.		0
232	Nodular Lymphocyte-Predominant Hodgkin Lymphoma. , 2014, , 343-352.		0
233	Anaplastic Large Cell Lymphoma. , 2014, , 111-120.		0
234	Waldenström's Macroglobulinemia. , 2014, , 303-329.		0

#	ARTICLE	IF	CITATIONS
235	Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma. , 2014, , 253-276.		0
236	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. Blood, 2014, 124, 2994-2994.	1.4	0
237	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667.	1.4	0
238	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. Blood, 2019, 134, 2027-2027.	1.4	0
239	The Mutational Landscape of Cold Agglutinin Disease. Blood, 2020, 136, 14-15.	1.4	0